FDA completes review of Minerva’s IND application for insomnia drug candidate MIN-202
MIN-202 is being developed by Minerva Neurosciences in collaboration with Janssen Pharmaceutica and Janssen Research & Development. The completion of the IND review will allow Janssen to start
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.